Загрузка...
553. A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir
BACKGROUND: Nucleoside reverse transcriptase inhibitors (NRTIs) may contribute to or exacerbate cardiovascular risk, bone loss, and renal dysfunction. Darunavir (DRV) and dolutegravir (DTG) have a high barrier to resistance and proven tolerability profile, but have not been well studied as part of a...
Сохранить в:
| Опубликовано в: : | Open Forum Infect Dis |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6255063/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.561 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|